Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Patient completed the ECU-NMO-301 trial~2. Patient has given written informed consent~Key Exclusion Criteria:~1. Patients who have withdrawn from the ECU-NMO-301 trial as a result of an AE related to trial drug~2. Female patients who are pregnant, breastfeeding, or intend to conceive during the course of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Eculizumab intravenous infusion every two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).